1/16
09:00 pm
vtgn
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
Neutral
Report
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
1/16
05:47 pm
vtgn
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors
Low
Report
Portnoy Law Firm Announces Class Action on Behalf of Vistagen Therapeutics, Inc. Investors
1/16
05:30 pm
vtgn
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Low
Report
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
1/16
05:06 pm
vtgn
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Low
Report
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
1/16
03:42 pm
vtgn
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Low
Report
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
1/16
02:36 pm
vtgn
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Low
Report
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
1/16
01:17 pm
vtgn
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (VTGN)
Low
Report
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (VTGN)
1/16
11:04 am
vtgn
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Vistagen Therapeutics, Inc. (VTGN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Low
Report
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Vistagen Therapeutics, Inc. (VTGN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
1/15
07:57 pm
vtgn
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
Low
Report
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action
1/15
06:03 pm
vtgn
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Vistagen Therapeutics, Inc. Common Stock and Sets a Lead Plaintiff Deadline of March 16, 2026
Medium
Report
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Vistagen Therapeutics, Inc. Common Stock and Sets a Lead Plaintiff Deadline of March 16, 2026
12/20
01:30 am
vtgn
VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by analysts at
Wall S
Low
Report
VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by analysts at
Wall S
12/1
08:30 am
vtgn
Vistagen Appoints Nick Tressler as Chief Financial Officer
High
Report
Vistagen Appoints Nick Tressler as Chief Financial Officer
11/26
08:30 am
vtgn
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
Low
Report
Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
11/18
07:58 am
vtgn
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 [Seeking Alpha]
Medium
Report
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 [Seeking Alpha]
11/17
12:08 pm
vtgn
VistaGen Therapeutics (NASDAQ:VTGN) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
VistaGen Therapeutics (NASDAQ:VTGN) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
11/14
12:27 am
vtgn
Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... [Yahoo! Finance]
Low
Report
Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... [Yahoo! Finance]
11/13
07:07 pm
vtgn
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript [Seeking Alpha]
Neutral
Report
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript [Seeking Alpha]
11/12
08:37 am
vtgn
What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings [Yahoo! Finance]
11/10
08:30 am
vtgn
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
Low
Report
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
11/5
08:30 am
vtgn
Vistagen to Participate in Stifel Healthcare Conference 2025
Medium
Report
Vistagen to Participate in Stifel Healthcare Conference 2025
11/3
08:30 am
vtgn
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
Low
Report
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
10/29
08:30 am
vtgn
Vistagen Appoints Paul Edick to its Board of Directors
Low
Report
Vistagen Appoints Paul Edick to its Board of Directors
10/21
01:24 pm
vtgn
VistaGen Therapeutics (NASDAQ:VTGN) had its "outperform" rating reaffirmed by analysts at William Blair.
Low
Report
VistaGen Therapeutics (NASDAQ:VTGN) had its "outperform" rating reaffirmed by analysts at William Blair.